RxDoctor Payments Data

Eric Sollenberger, MD

Ophthalmology · Knoxville, TNNPI 1518314350

Payments from drug & device makers

$3,188in general payments, 2019–2025

Across 57 payments — averaging $55.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • AstraZeneca$224
  • AbbVie$198
  • Carl Zeiss Meditec, Inc.$192
  • Johnson & Johnson Surgical Vision, Inc.$160
  • TG Therapeutics, Inc.$125
  • plus $388 from 7 others

What the payments were for

  • Food & beverage$3,188100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,188 in reported general payments places this provider in the 65th percentile of 323 ophthalmology providers in Tennessee.

See all ophthalmology providers in Tennessee

Medicare billing

Part B allowed, 2024
$430,175
Medicare patients
1,228
Services billed
3,747

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost78$40,104
RocklatanNetarsudil Mesylat/Latanoprost39$19,377
Prednisolone Acetate373$17,576
XiidraLifitegrast11$7,391
MoxifloxacinMoxifloxacin Hcl251$5,532
ZirganGanciclovir12$5,409
Travoprost45$5,271
Latanoprost527$4,934
RhopressaNetarsudil Mesylate15$4,847
Timolol Maleate238$4,755
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat303$4,496
Brimonidine Tartrate115$4,458
ValacyclovirValacyclovir Hcl60$3,629
Ketorolac Tromethamine118$2,581
Fluorometholone15$1,529

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$198$40,10478 claims
Bausch & Lomb Americas Inc.Xiidra, Zirgan$81$12,80123 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 323 ophthalmology providers in Tennessee.

Other ophthalmology in Knoxville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →